š VC round data is live in beta, check it out!
Lupin Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lupin and similar public comparables like Exelixis, Dr Reddy's Laboratories, Elanco, RemeGen and more.
Lupin Overview
About Lupin
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.
Founded
1983
HQ
Employees
26.2K
Website
Sectors
Financials (LTM)
EV
$11B
Lupin Financials
Lupin reported last 12-month revenue of $3B and EBITDA of $831M.
In the same LTM period, Lupin generated $2B in gross profit, $831M in EBITDA, and $549M in net income.
Revenue (LTM)
Lupin P&L
In the most recent fiscal year, Lupin reported revenue of $3B and EBITDA of $620M.
Lupin expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $831M | XXX | $620M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $549M | XXX | $392M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | ā | ā | $338M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lupin Stock Performance
Lupin has current market cap of $11B, and enterprise value of $11B.
Market Cap Evolution
Lupin's stock price is $24.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11B | $11B | 0.3% | XXX | XXX | XXX | $0.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLupin Valuation Multiples
Lupin trades at 3.9x EV/Revenue multiple, and 13.7x EV/EBITDA.
EV / Revenue (LTM)
Lupin Financial Valuation Multiples
As of April 18, 2026, Lupin has market cap of $11B and EV of $11B.
Equity research analysts estimate Lupin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lupin has a P/E ratio of 20.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 13.7x | XXX | 18.3x | XXX | XXX | XXX |
| EV/EBIT | 16.3x | XXX | 23.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | 7.2x | XXX | XXX | XXX |
| P/E | 20.8x | XXX | 29.1x | XXX | XXX | XXX |
| EV/FCF | 30.3x | XXX | 80.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lupin Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lupin Margins & Growth Rates
Lupin's revenue in the last 12 month grew by 5%.
Lupin's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Lupin's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lupin's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Lupin Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | (6%) | XXX | 34% | XXX | XXX | XXX |
| Rule of 40 | ā | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | ā | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | ā | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | ā | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | ā | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | ā | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lupin Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lupin | XXX | XXX | XXX | XXX | XXX | XXX |
| Exelixis | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr Reddy's Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Elanco | XXX | XXX | XXX | XXX | XXX | XXX |
| RemeGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Financiere de Tubize | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lupin M&A Activity
Lupin acquired XXX companies to date.
Last acquisition by Lupin was on XXXXXXXX, XXXXX. Lupin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lupin
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLupin Investment Activity
Lupin invested in XXX companies to date.
Lupin made its latest investment on XXXXXXXX, XXXXX. Lupin invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lupin
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lupin
| When was Lupin founded? | Lupin was founded in 1983. |
| Where is Lupin headquartered? | Lupin is headquartered in India. |
| How many employees does Lupin have? | As of today, Lupin has over 26K employees. |
| Who is the CEO of Lupin? | Lupin's CEO is Vinita D. Gupta. |
| Is Lupin publicly listed? | Yes, Lupin is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Lupin? | Lupin trades under LUPIN ticker. |
| When did Lupin go public? | Lupin went public in 2001. |
| Who are competitors of Lupin? | Lupin main competitors are Exelixis, Dr Reddy's Laboratories, Elanco, RemeGen. |
| What is the current market cap of Lupin? | Lupin's current market cap is $11B. |
| What is the current revenue of Lupin? | Lupin's last 12 months revenue is $3B. |
| What is the current revenue growth of Lupin? | Lupin revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Lupin? | Current revenue multiple of Lupin is 3.9x. |
| Is Lupin profitable? | Yes, Lupin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lupin? | Lupin's last 12 months EBITDA is $831M. |
| What is Lupin's EBITDA margin? | Lupin's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Lupin? | Current EBITDA multiple of Lupin is 13.7x. |
| What is the current FCF of Lupin? | Lupin's last 12 months FCF is $375M. |
| What is Lupin's FCF margin? | Lupin's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Lupin? | Current FCF multiple of Lupin is 30.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.